1. Fig. 2. Type 1 immunity drives metabolic disease but protects against NAFLD.
Type 1 immunity drives metabolic disease but protects against NAFLD. WT (circles), IL-4−/− (squares), and IL-10/IL-4−/− (triangles) mice were maintained on a normal diet (filled symbols) or HFD (open symbols) for 15 weeks. Obesity was measured by magnetic resonance imaging (MRI) body composition (A) (n = 4 to 6), and serum leptin levels were assessed by enzyme-linked immunosorbent assay (n = 3 to 7) (B). NAFLD progression was assessed by liver weight and indices (n = 8 to 15) (C), hepatic triglyceride measurement (n = 8 to 11), serum aminotransferase levels (n = 4 to 17) (D), and Giemsa-stained liver sections (E). KO, knockout. Adipose inflammation was assessed through histological analysis of H&E-stained adipose sections (scale bars, 150 μm) (F), adipose tissue expression of tnf and ccl2 (n = 3 to 11) (G), and flow cytometry analysis of adipose eosinophils (n = 4 to 11) (H). All data points represent a single mouse, and representative or pooled data from two or more independent experiments are shown (two-tailed t tests, n = 2 to 10; *P < 0.05, **P < 0.01, ***P < 0.005, ****P < ).
Kevin M. Hart et al., Sci Transl Med 2017;9:eaal3694
Published by AAAS